BNP Paribas Financial Markets’s KalVista Pharmaceuticals KALV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$45.7K Buy
4,041
+1,292
+47% +$14.6K ﹤0.01% 3477
2025
Q1
$31.7K Sell
2,749
-3,503
-56% -$40.4K ﹤0.01% 3590
2024
Q4
$53K Sell
6,252
-37,044
-86% -$314K ﹤0.01% 3558
2024
Q3
$501K Buy
43,296
+40,280
+1,336% +$466K ﹤0.01% 2159
2024
Q2
$35.5K Sell
3,016
-14,997
-83% -$177K ﹤0.01% 2856
2024
Q1
$214K Buy
18,013
+8,750
+94% +$104K ﹤0.01% 2572
2023
Q4
$113K Buy
9,263
+5,573
+151% +$68.3K ﹤0.01% 2650
2023
Q3
$35.5K Sell
3,690
-9,112
-71% -$87.7K ﹤0.01% 2831
2023
Q2
$115K Buy
12,802
+885
+7% +$7.97K ﹤0.01% 2602
2023
Q1
$93.7K Buy
11,917
+5,808
+95% +$45.7K ﹤0.01% 2710
2022
Q4
$41.3K Sell
6,109
-1,134
-16% -$7.67K ﹤0.01% 2797
2022
Q3
$105K Buy
7,243
+1,285
+22% +$18.6K ﹤0.01% 3042
2022
Q2
$58.6K Buy
5,958
+4,189
+237% +$41.2K ﹤0.01% 2885
2022
Q1
$26.1K Sell
1,769
-3,003
-63% -$44.3K ﹤0.01% 3114
2021
Q4
$63.1K Buy
4,772
+1,173
+33% +$15.5K ﹤0.01% 3056
2021
Q3
$62.8K Buy
3,599
+2,831
+369% +$49.4K ﹤0.01% 2853
2021
Q2
$18.4K Sell
768
-7,606
-91% -$182K ﹤0.01% 2956
2021
Q1
$215K Buy
8,374
+5,417
+183% +$139K ﹤0.01% 2465
2020
Q4
$56.2K Sell
2,957
-581
-16% -$11K ﹤0.01% 2850
2020
Q3
$44.5K Buy
3,538
+2,390
+208% +$30.1K ﹤0.01% 2902
2020
Q2
$13.9K Sell
1,148
-3,456
-75% -$41.8K ﹤0.01% 2935
2020
Q1
$35.2K Buy
4,604
+2,803
+156% +$21.4K ﹤0.01% 3100
2019
Q4
$32.1K Buy
1,801
+327
+22% +$5.82K ﹤0.01% 3192
2019
Q3
$17.1K Buy
1,474
+1,406
+2,068% +$16.3K ﹤0.01% 3371
2019
Q2
$1.51K Buy
+68
New +$1.51K ﹤0.01% 3718
2016
Q1
Sell
-200
Closed -$10.2K 2880
2015
Q4
$10.2K Buy
200
+3
+2% +$152 ﹤0.01% 3403
2015
Q3
$9.86K Buy
+197
New +$9.86K ﹤0.01% 3427